secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0001493152-23-010655
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enveric Biosciences reports FY2022 net loss of $19.3M; advances EB-373 toward Phase 1 in Q4 2023
--------------------------------------------------------------------------------

- Comprehensive net loss $19.3M for FY2022 vs $48.8M in FY2021; diluted loss per share $13.00.
- Cash and cash equivalents $17.7M, working capital $14.4M as of Dec. 31, 2022.
- Lead candidate EB-373 nominated from EVM201 Series; Phase 1 trial planned for Q4 2023 in Australia.
- Appointed Kevin Coveney as CFO and Lynn Gallant as VP Clinical Operations during year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000149315223010655/0001493152-23-010655-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000149315223010655/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-010655

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer